7Stewart J S, Cohen E E, Licilra L, et al. Phase Ⅲ sludy of ge fitinib compared with intravenous metholrexate for recurrent squa mous cell carcinoma of the head and neckEcorrected[J]. J Clin Oncol, 2009,27: 1864- 1871. 被引量:1
8Izzedine H, Ederhy S, Goldwasser F, et al. Management of hyper- tension in angiogenesisinhibitor treated patients[J]. Ann Oncol, 2009,20:807-815. 被引量:1
9Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatoeellular carcinorna[J]. N Engl J Med,2008,359:378-390. 被引量:1
10Chen H X, Cleck J N. Adverse effects of antfcancer agents that target the VEGF pathway[J]. Nat Rev Clin Oncol,2009,8:465-477. 被引量:1
5Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma[J]. Nature biotechnology,2012,30(7 ) :631 - 637. 被引量:1